Have a feature idea you'd love to see implemented?
Let us know!
ANAB Anaptysbio Inc
Price (delayed)
$14.55
Market cap
$442.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.08
Enterprise value
$267.65M
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients
Highlights
The company's gross profit has surged by 88% QoQ
ANAB's revenue has soared by 88% from the previous quarter
The company's quick ratio rose by 13% QoQ but it fell by 5% YoY
The net income has decreased by 12% YoY but it has increased by 2.6% QoQ
Anaptysbio's equity has decreased by 30% YoY
Key stats
What are the main financial stats of ANAB
Market
Valuations
Earnings
Shares outstanding
30.43M
Market cap
$442.74M
Enterprise value
$267.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.73
Price to sales (P/S)
7.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.68
Revenue
$57.17M
Gross profit
$57.17M
Net income
-$165.66M
EBIT
-$165.65M
EBITDA
-$163.25M
Free cash flow
-$103.39M
Per share
Balance sheet
Liquidity
EPS
-$6.08
EPS diluted
-$6.08
Free cash flow per share
-$3.58
Book value per share
$3.07
Revenue per share
$1.98
TBVPS
$17.08
Total assets
$493.42M
Total liabilities
$409.05M
Debt
$16.49M
Equity
$84.37M
Working capital
$404.8M
Debt to equity
0.2
Current ratio
10.23
Quick ratio
10.08
Net debt/EBITDA
1.07
Margins
Efficiency
Dividend
EBITDA margin
-285.5%
Gross margin
100%
Net margin
-289.8%
Operating margin
-257.8%
Return on assets
-37.2%
Return on equity
-287.9%
Return on invested capital
-49.4%
Return on capital employed
-36.8%
Return on sales
-289.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANAB stock price
How has the Anaptysbio stock price performed over time
Intraday
-3%
1 week
-6.67%
1 month
-28.36%
1 year
-25.42%
YTD
-32.07%
QTD
-56.57%
Financial performance
How have Anaptysbio's revenue and profit performed over time
Revenue
$57.17M
Gross profit
$57.17M
Operating income
-$147.41M
Net income
-$165.66M
Gross margin
100%
Net margin
-289.8%
The company's gross profit has surged by 88% QoQ
ANAB's revenue has soared by 88% from the previous quarter
The company's operating margin has surged by 74% YoY and by 52% QoQ
ANAB's net margin has soared by 71% YoY and by 48% from the previous quarter
Growth
What is Anaptysbio's growth rate over time
Valuation
What is Anaptysbio stock price valuation
P/E
N/A
P/B
4.73
P/S
7.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.68
ANAB's EPS is down by 12% year-on-year but it is up by 4.3% since the previous quarter
ANAB's P/B is 81% lower than its last 4 quarters average of 24.8 and 29% lower than its 5-year quarterly average of 6.7
Anaptysbio's equity has decreased by 30% YoY
ANAB's revenue has soared by 88% from the previous quarter
The stock's price to sales (P/S) is 79% less than its 5-year quarterly average of 34.2 and 70% less than its last 4 quarters average of 24.8
Efficiency
How efficient is Anaptysbio business performance
ANAB's return on sales has surged by 71% year-on-year and by 48% since the previous quarter
The return on invested capital has dropped by 56% year-on-year and by 9% since the previous quarter
The ROA has decreased by 36% YoY but it has increased by 3.1% QoQ
Anaptysbio's return on equity has decreased by 13% QoQ
Dividends
What is ANAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANAB.
Financial health
How did Anaptysbio financials performed over time
The total assets is 21% more than the total liabilities
The total assets has grown by 15% from the previous quarter
The company's quick ratio rose by 13% QoQ but it fell by 5% YoY
ANAB's debt is 80% less than its equity
ANAB's debt to equity has dropped by 88% since the previous quarter but it is up by 33% year-on-year
Anaptysbio's equity has decreased by 30% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.